CoChat
Sign Up
Cited by 745

The DOI matches its Crossref record.

Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy

Olivotto, Iacopo, Cecchi, Franco, Casey, Susan A., Dolara, Alberto, Traverse, Jay H., Maron, Barry J.·2001·Circulation
DOI 10.1161/hc4601.097997
Open this paper in CoChat — free account

Abstract

Background Clinical impact of atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) is largely unresolved. Thus, we analyzed the prognostic implications of AF in a large, community-based HCM population assembled from Italian and US cohorts. Methods and Results Occurrence of AF and outcome were assessed in 480 consecutive HCM patients (age at diagnosis, 45±20 years; 61% male) who were followed up for 9.1±6.4 years. AF occurred in 107 patients (22%; incidence, 2%/y) and was independently predicted by advancing age, congestive symptoms, and increased LA size at diagnosis. Patients with AF had increased risk for HCM-related death (OR, 3.7; P <0.002) because of excess heart failure–related mortality but not sudden, unexpected death. This risk associated with AF was substantially greater in patients with outflow obstruction or with earlier development of AF (≤50 years of age). AF patients were also at increased risk for stroke (OR, 17.7; P =0.0001) and severe functional limitation (OR for NYHA class III or IV, 2.8; P <0.0001). Compared with those with exclusively paroxysmal AF, patients developing chronic AF showed higher combined probability of HCM-related death, functional impairment, and stroke ( P <0.0001). In a subgroup of 37 patients with AF (35%), the clinical course was largely benign in the absence of stroke and severe symptoms. Conclusions In a community-based HCM population, AF (1) was common, with 22% prevalence over 9 years; (2) was associated with substantial risk for heart failure–related mortality, stroke, and severe functional disability, particularly in patients with outflow obstruction, those ≤50 years of age, or those developing chronic AF; and (3) was nevertheless compatible with benign outcome in 35% of patients.

Overview

Integrity signals

Registry

Crossref · 10.1161/hc4601.097997

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with atrial fibrillation have more symptoms, with greater functional limitation, particularly with progression to permanent atrial fibrillation.

    “patients with atrial fibrillation have more symptoms, 115 with greater functional limitation, particularly with progression to permanent atrial fibrillation.”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [113]

  • Atrial fibrillation is common in hypertrophic cardiomyopathy, being present in 5% at the time of diagnosis and developing in another 10-22% during follow-up.

    “Atrial fibrillation is common in hypertrophic cardiomyopathy, being present in 5% at the time of diagnosis and developing in another 10-22% during follow-up.”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [113]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997; 12;350: 127–133.
  2. 10.1056/NEJM199703133361107 · DOI
  3. 10.1136/hrt.46.2.168 · DOI
  4. 10.1016/0735-1097(95)00353-3 · DOI
  5. 10.1001/jama.281.7.650 · DOI
  6. 10.1136/hrt.32.5.652 · DOI
  7. 10.1016/S0735-1097(86)80484-3 · DOI
  8. 10.1161/str.15.2.6538354 · DOI
  9. 10.1253/jcj.61.673 · DOI
  10. 10.1016/S0735-1097(10)80014-2 · DOI · Paper page
  11. 10.1016/S0735-1097(10)80015-4 · DOI
  12. 10.1016/0002-9149(92)90939-V · DOI
  13. 10.1016/S0002-9149(99)00043-0 · DOI
  14. 10.1136/hrt.78.1.44 · DOI
  15. 10.1053/euhj.1998.1050 · DOI
  16. 10.1161/circ.102.8.858 · DOI
  17. 10.1016/0735-1097(95)00390-8 · DOI
  18. 10.1056/NEJM198204293061703 · DOI
  19. 10.1016/0002-9149(83)90317-X · DOI
  20. 10.1016/0002-9149(94)90151-1 · DOI
  21. 10.1016/S0735-1097(00)01019-6 · DOI
  22. 10.1016/0735-1097(89)90302-1 · DOI
  23. 10.1056/NEJM200003303421302 · DOI

Cited by

Sorted by citations

Metadata

Authors
Olivotto, I., Cecchi, F., Casey, S. A., Dolara, A., Traverse, J. H., & Maron, B. J.
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2001-11-20
Volume
104
Issue
21
Pages
2517-2524
ISSN
  • 0009-7322
  • 1524-4539
DOI
10.1161/hc4601.097997
Cited by
745
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review